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ABSTRACT 
 
Background. Neoangiogenesis is crucial in plaque progression and instability. Previous 
data from our group demonstrated that intra-plaque neovessels show both a 
Nestin+/WT+ and a Nestin+/WT1- phenotype, the latter being correlated with 
complications and plaque instability. 
Aims. The aims of the present thesis are: (i) to confirm our previous results on 
Nestin/WT1 phenotype in a larger series of carotid atheromatous plaques, (ii) to 
evaluate the relationship between the Nestin+/WT1- neoangiogenesis phenotype and 
plaque morphology, (iii) to evaluate the relationship between the immunohistochemical 
and histopathological characteristics and the clinical instability of the plaques. 
Materials and Methods. Seventy-three patients (53 males, 20 females, mean age 71 
years) were consecutively enrolled. Symptoms, brain CT scan, 14 histological variables, 
including intraplaque hemorrhage and diffuse calcifications, were collected. 
Immunohistochemistry for CD34, Nestin and WT1 was performed. RT-PCR was 
performed to evaluate Nestin and WT1 mRNA (including 5 healthy arteries as controls). 
Results. Diffusely calcified plaques (13 out of 73) were found predominantly in females 
(P=0.017), with a significantly lower incidence of symptoms (TIA/stroke) and brain 
focal lesions (P=0.019 and P=0.013 respectively) than not-calcified plaques, but with 
the same incidence of intraplaque complications (P=0.156). Accordingly, both calcified 
and not calcified plaques showed similar mean densities of positivity for CD34, Nestin 
and WT1. The density of Nestin and WT1 correlated with the occurrence of intra-plaque 
hemorrhage in all cases, while the density of CD34 correlated only in not-calcified 
plaques. 
Conclusions. We confirmed that the Nestin+/WT1- phenotype characterizes the 
neovessels of instable plaques, regardless the real amount of CD34-positive 
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neoangiogenesis. The calcified plaques show the same incidence of histological 
complications, albeit they do not influence symptomatology and plaque vulnerability. 
Female patients show a much higher incidence of not-complicated or calcified plaques, 
receiving de facto a sort of protection compared to male patients. 
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OVERVIEW OF THE PHD PROJECT 
The principal aims of the current PhD program is the evaluation of the neoangiogenesis 
in carotid atheromatous plaques, in term both of neovessel density and phenotype, and 
its correlation with plaque morphology and instability. 
We performed a morphological and immunohistochemical study on 73 carotid plaques, 
in order to evaluate the phenotype of the intra-plaque neovessels, and its relationship 
with plaque morphology and clinical presentation. In previous studies conducted during 
the PhD program, we found that specific vasa vasorum of normal arteries co-express 
Nestin and WT1, two markers of progenitor endothelia and vascular proliferative 
potential. Those results were published in 2012 [Vasuri F, Fittipaldi S, Buzzi M, 
Degiovanni A, Stella A, D'Errico-Grigioni A, Pasquinelli G. Nestin and WT1 expression 
in small-sized vasa vasorum from human normal arteries. Histol Histopathol 
2012;27:1195-1202], and gave us a theoretical basis for the evaluation of Nestin and 
WT1 in plaque neovessels. During the second year of the PhD program, we evaluated 
CD34, Nestin and WT1 in 49 specimens, and we found that intra-plaque neovessels 
express both the Nestin+/WT1+ phenotype and the Nestin+/WT1- phenotype, i.e. the 
WT1/Nestin ratio was inferior than 1. Moreover, the Nestin+/WT1- phenotype 
correlated with the occurrence of intra-plaque histological complications (and plaque 
vulnerability) regardless the density of CD34-positive vessels. These results are under 
revision [Fittipaldi S, Vasuri F, Degiovanni A, Pini R, Mauro R, Faggioli G, D'Errico-
Grigioni A, Stella A, Pasquinelli G. Nestin and WT1 expression in atheromatous plaque 
neovessels: association with vulnerability. Histol Histopathol]. 
The results exposed in the present thesis are the progression of our study, with an 
enlargement of the carotid specimen series (n=73), and special focus on the different 
neoangiogenetic profiles in neovessel of plaques with different morphology, and on the 
correlations with clinical data.  
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1.1 FUNCTIONAL ANATOMY OF THE NORMAL ARTERIAL INTIMA 
(from Stary 1992) 
 
The intima is defined as the portion of the arterial wall from the endothelium to the 
media margin (generally the internal elastica lamina, albeit it can be missing in branches 
and bifurcations). The intima/media ratio can vary from 0.1 to 1 according to the 
anatomical site. The arterial intima is composed by two layers, whose identification is 
not always easy at light microscopy (Stary 1992): 
(1) An inner layer called proteoglycan layer, containing finely reticulated not-
fibrous connective tissue (proteoglycan) and very few elastic fibers. The 
proteoglycan layer contains both RER-rich (synthetic) and myofilament-rich 
(contractile) smooth-muscle cells, and it was firstly described as an alcianophilic 
inner region of the intima in the nonhuman primates (Wight 1975). 
(2) An outer layer called musculoelastic layer, with abundant contractile smooth-
muscle cells and elastic fibers, and the presence of more collagen. 
 
Figure 1 (Reprinted by Stary et al. 1992). Coronary 
artery from a 16-month-old boy, showing the 
different layers composing a healthy vessel wall.  
e: endothelium; pgc: proteoglycan-rich layer; me: 
musculoelastic layer; M: media; A: adventitia. 
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1.1.1 Prevalent cell types in the normal intima 
Endothelial cells of normal arteries (both muscular and elastic) are flattened and 
elongated cells forming a continuous layer. Studies on animal cultured cells 
demonstrated that the long axis of each endothelial cell is oriented in the direction of the 
blood flow (Flaherty 1972; Levesque 1985). Polysaccharides, glycosaminoglycans and 
glycoproteins form the glycocalix that covers the luminal portion of endothelium; some 
of these molecules are known to bind lectins, lipoprotein lipase, and other enzymes. 
Moreover, endothelial cells surface shows membrane receptors for LDL (with 
lipoprotein-lipase activity), insulin, and histamine, among others (Dicorleto 1975; 
Simionescu 1981; Bar 1982; Heltianu 1982; Wang-Iverson 1982; Jaffe 1987). 
Endothelial cells carry out several roles, such as the transport of macromolecules 
(lipoproteins above all) from the blood flow to the intima, the anti-thrombotic 
homeostasis, the regulation of inflammation and of the response to immunity, as well as 
the maintenance of the vascular tone and vasoconstriction. Endothelial cytoplasms 
contain thrombomodulin, whose binding with thrombin inactivates the coagulation 
factor Va (Esmon 1988). Furthermore, the endothelial-derived prostacyclin PGI2 
inhibits the platelet aggregation and cause vasodilatation (Moncada 1977). Other 
endothelial-derived factors are likely to promote both vasodilatation and 
vasoconstriction (Brenner 1989), while the same effects are obtained by soluble 
mediators with direct action on endothelial receptors, as for serotonin (Vanhoutte 1987), 
acetylcholine (Furchgott 1980), and endothelin (the latter produced by the endothelium 
itself) (Yanagisawa 1988). 
 
Two types of smooth muscle cells are usually recognizable in the normal intima of 
humans and other species:  
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(1) The myofilament-rich smooth muscle cells, also called contractile or adult-type 
(Dilley 1987), are the main type in human intima. 
(2) The rough endoplasmic reticulum (RER)-rich smooth muscle cells, also called 
synthetic, immature, modulated or ergastoplasm-rich (Dilley 1987), contain few 
contractile filaments, and they are more frequently visible in proteoglycan-rich 
intimal layer, since RER-rich smooth muscle cells can synthesize a wide set of 
matrix molecules (Burke 1979). 
Apart from the contractile and synthetic functions, intimal smooth muscle cells are 
likely to play a role in the removal via phagocytosis of LDL and other lipoproteins from 
the intima, as it is demonstrated by the expression of LDL receptors on smooth muscle 
cells surface (Stary 1992). 
 
Inactivated macrophages are physiologically present in the human intima, and their 
number increases from the childhood to adult life. Like in several healthy tissues, 
macrophages are present in intima as isolated mononuclear cells: they carry out several 
functions, such as the production of enzymes for matrix remodeling (elastases, 
collagenases), the secretion of growth factors for smooth muscle, neoangiogenesis, 
lymphocytes chemotaxis, phagocytosis of lipoproteins, bacteria, necrotic cells and 
immune complexes (Werb 1975; Nucera 2011). 
 
1.1.2 Extracellular matrix in the normal intima 
The extracellular matrix constitutes up to 60% of the intima, both in healthy condition 
and during intimal thickenings. Apart from molecules responsible for the cell-cell and 
cell-matrix adhesion, like fibronectin and laminin, the most represented molecule types 
in intimal extracellular matrix are proteoglycans, collagen and elastin. 
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Proteoglycans production by the endothelium cells has been demonstrated on bovine 
aorta cultured cells, and in particular heparan sulfate proteoglycan and, in a minor 
amount, dermatan sulfate proteoglycan (Kinsella 1988). In human aortic media, 
dermatan sulfate proteoglycan resulted to be more associated with collagen fibers, and 
heparan sulfate proteoglycan with elastic fibers and smooth muscle cells. The different 
proteoglycans in their different localizations play an important role in maintaining the 
viscoelastic properties of the vessel wall, and therefore in controlling the homeostasis of 
vascular wall cells (Wight 1989). 
Collagen is involved in the vascular wall integrity by constituting the attachment site of 
the endothelial cells with the intimal extracellular matrix. The most represented collagen 
types in the artery wall are type I and type III. In children, the type III collagen (of 
endothelial derivation) is the prevalent type of collagen present in the subendothelial 
region, but with aging the synthesis of collagen type I increases, probably due to the 
concomitant increasing of smooth muscle cells, capable to synthesize both collagen type 
I and type III in vitro (Sage 1981; Sankey 1981). 
Elastin in produced by endothelial cells and smooth muscle cells: in the intimal 
musculoelastic layer elastic fibers are prominent, similar to those present in the media 
layer. With aging there is a decreasing in elastin content and an increasing in collagen 
content (Hosoda 1984). 
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1.2 PATHOBIOLOGY OF ATHEROSCLEROSIS 
 
1.2.1 Atherosclerosis as an inflammatory disease 
(from Ross 1999) 
After the birth a progressive increase of the intimal thickness was described in some 
districts. In studies conducted on rabbits by means of tritiated thymidine, this increase is 
likely to be due to a mitotic numerical growth of the pre-existing smooth muscle cells 
(Stary 1974). Anyway it is not still clear whether the migration of smooth muscle cells 
from the media layer might play a role (Grotendorst 1981). 
A part these adaptive changes characterizing some specific human vascular districts, the 
onset of atherosclerotic lesions is correlated to specific events. According to the 
historical definition, the first event triggering atherosclerotic lesions is a damage of the 
endothelial surface (Ross 1973), although more recent theories emphasized an 
endothelial dysfunction, rather than damage, to play a key role in the lesion initiation. 
The causes of endothelial dysfunction that were identified and described in the years are 
multiple, from LDL or homocysteine plasma levels, to diabetes and genetic diseases, 
from cigarette smoking to viruses such as herpervirus, Chlamydia, etc. (Ross 1999). 
According to Ross, after the initial damage, the endothelium acquires pro-coagulant 
properties (instead of anti-coagulant), and starts the production and secretion of 
vasoactive factors, cytokines and growth factors. The result is an actual inflammatory 
response to the initial stimulus, characterized mainly by lymphocytes and 
monocytes/macrophages (Jonasson 1986; van der Wal 1989), which is soon followed by 
a migration of the medial smooth muscle cells. With the maintaining of the 
inflammation, the artery wall thickens and dilates, resulting in a remodeling of the wall, 
without modifications of the lumen. 
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Different cycles of inflammatory and muscle cell accumulation, more serum fat 
entrapment, and the activation of fibrosis by cytokines lead to the formation of a necro-
lipidic core and of a fibrous cap, which characterize the so-called advanced lesions. At 
this point the lesion may protrude in the lumen, leading to stenosis and symptoms. 
 
1.2.2 Main risk factors 
 LDL. Circulating LDL represent the major cause of endothelium and arterial 
wall injury, and they are commonly found in the modified forms: oxidized, 
proteoglycan-associated or glycated forms, the latter most commonly in diabetes 
(Morel 1983; Griendling 1997). The phagocitosis by the macrophages lead to 
LDL oxidation, the formation of lipid peroxides and the accumulation of esters 
of the cholesterol; in these phase the macrophage becomes a "foam cell". The 
pro-inflammatory cytokines tumor necrosis factor-α and interleukin-1, among 
others, have shown a facilitative role in LDL binding to the endothelium surface, 
increasing the expression of the gene encoding LDL receptors (Stopeck 1993). 
 Hypertension. Hypertension is connected to the pathogenesis of atherosclerosis 
through different mechanisms: the activation of the renin-angiotensin system 
leads to systemic vasoconstriction, and a proliferative stimulus on muscle cells 
has been described to occur with time. The binding of angiotensin II to specific 
receptors on the surface of the smooth muscle cells leads also to the activation of 
phospholipase C, that causes muscle hypertrophy and hyperoxidation of LDL 
(Gibbons 1992). 
 Homocysteine. Homocysteine is toxic for the endothelium, and according to 
several studies it showes pro-thrombotic and fibrogenic activities (Harker 1993; 
Hajjar 1993). When serum homocysteine is elevated in patients with no deficit 
of homocysteine metabolism, there is an increasing risk of symptomatic 
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atherosclerosis (Verhoef 1995), while in patients with congenital enzymatic 
deficits which lead to an impaired homocysteine metabolism, a severe 
atherosclerosis can develop also in childhood (Nygard 1997). 
 C-Reactive Protein (CRP). Cardiovascular diseases and diabetes are 
inflammatory diseases, and many serum inflammatory markers have been 
studied in the past years (Devaraj 2009). Among them, CRP is considered the 
best marker to predict the severity and course of the metabolic syndrome 
(Ridker 2000). High-sensitivity CRP has been found to interact with a number of 
pro-inflammatory processes in vitro, and it is able to induce the expression of 
the adhesion molecules VCAM-1 and ICAM-1 in humans (Corrado 2010). C-
reactive protein levels rise with increasing levels of visceral adipose tissue, and 
together with other adipose-derived modulators of inflammation evoke the 
production of acute phase reactants in the liver, implicated in thrombogenesis 
(Libby 2010). 
 Other risk factors include smoking, insulin resistance/diabetes, lack of physical 
activity, etc. All these factors result in direct or indirect endothelial dysfunction 
and inflammation of the vessel wall. The same concept is applicable for Lupus 
Erithematosus Systemicus and other systemic disease which may cause 
vasculitis. 
 
1.2.3 Plaque progression and neoangiogenesis 
The vulnerable plaques have been originally described as atheromatous plaques with a 
large lipid core, a thin fibrous cap, a rich infiltrate of macrophages and scarce smooth 
muscle cells (Kullo 1998). The erosion and rupture of the fibrous cap is the main events 
triggering the plaque instability. The degradation of the fibrous cap is mediated by 
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metalloproteases, such as collagenases, elastases and stromelysin (Galis 1994), mainly 
produced by macrophages in response to cytokines produced by activated T-cells. 
More recently, neoangiogenesis stood out as one of the most important pathological 
processes involved in the plaque progression (Hermus 2010), since neovessel formation 
was related to increased plaque vulnerability and to the onset of clinical symptoms 
(Mofidi 2001; Faggioli 2011).  
Mofidi et al. have found a higher volume of intraplaque hemorrhage and a higher 
incidence of symptoms in those plaques with a higher neovessel density, measured with 
a "simple" immunohistochemistry for CD34 (Mofidi 2001). 
The key mechanism triggering plaque neoangiogenesis is the hypoxia of the inner 
vascular layers due to the lipid accumulation and the myo-intimal thickening up to 500 
µm (Moreno 2006). The chronic hypoxia activates different pathways, such as the 
Hypoxia Inducible Factor and the Toll-like receptor pathways (Frantz 2005), leading to 
a neoangiogenesis which is thought to originate from the sprouting of the endothelial 
cells of the post-capillary venules (Carmeliet 2003). Our recent results indicate that the 
vasa vasorum located in specific adventitial "hot spots" are likely to represent the 
candidate vessels of origin of the neoangiogenesis during atherosclerosis (Vasuri 2012). 
Anyway, the adventitial origin of the neoangiogenetic vessels is not the only origin 
described: for example, a previous work from Kumamoto and colleagues identified the 
luminal endothelium as the source of the 3.5% of the intra-plaque neovessels 
(Kumamoto 1995). 
If the density of neovessels is likely to be directly related with plaque growth and 
progression (Moreno 2006), also the morphology of the neoangiogenetic structures is 
important for the onset of plaque instability: indeed, it was described that plaque 
neovessels lack extracellular junctions (Sluimer 2009), and that symptomatic plaques 
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showed larger and more irregular neoangiogenetic structures compared to the 
neovessels of asymptomatic plaques (McCarthy 1999). 
The neoangiogenesis has been involved also in the plaque regression mechanisms, since 
the neovessels are responsible for the lipid transport outside the plaque core. After lipid 
removal, the plaque becomes fibrotic (type Vc or type VIII according to AHA, see the 
next chapter) or calcified (type Vb or type VII), and in these regressed plaques a minor 
neovessel density was described (Moreno 2006). 
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1.3 PATHOLOGIC ANATOMY OF THE INTIMAL LESIONS: THE 
AMERICAN HEART ASSOCIATION (AHA) CLASSIFICATION 
 
The original classification of the American Heart Association (AHA), after a paper by 
Stary et al. in 1994, sorted the intimal lesions into six bio-pathological entities, which in 
turn were pooled in two main groups: the so-called precursor lesions (types I, II, III), 
and the advanced lesions (types IV, V, VI) (Stary 1994; Stary 1995). The progression 
from one type to another is not demonstrated for every lesion, and studies on animal 
models have shown that a specific sequence of steps is required to progress from the 
"simple" lipid intimal accumulation (which characterize the precursor lesions) to the 
intimal thickening and related disorders, with the consequent deformation of the whole 
arterial wall (advanced lesions). 
The first step of the whole process is represented by the entrapment of serum 
lipoproteins in the matrix intima, and their internalization by the macrophages and 
smooth muscle cells (Schwenke 1989; Steinberg 1990). The following oxidation of the 
lipoproteins represents a chemotactic stimulus for monocytes (Quinn 1987). 
In the study of the atheromatous disease, a particular kind of "gelatinous lesion" has 
been proposed as precursor lesion: according to some authors, this lesion appears as 
oval-shaped intimal elevation, pink to pale grey , and soft. At histology, these 
thickening areas contain gelatinous scarcely-cellulated material, with little or no lipids, 
and constituted by abundant matrix with little collagen and elastin content (Movat 1959; 
Haust 1971). 
 
1.3.1 AHA classification of intimal lesions: initial and intermediate lesions 
 Type I lesions ("initial lesions"). It represents the most frequent intimal lesion in 
childhood (Stary 1994), and it is constituted by isolated groups of macrophages 
Introduction 
 
12 
 
with cytoplasmic lipid droplets ("foam cells") (Stary 1989). These findings are 
observed in the same arterial regions generally prone to the hyperplasia of the 
eccentric type. 
 
 
Figure 2. Isolated clusters of intimal macrophagic foam cells. 
Haematoxylin-Eosin stain; magnification 20x. 
 
 Type II lesions (including fatty streaks). In this step, the foam cells are not 
grouped in isolated clusters, but they form stratified layers in the intima. If the 
layers are located immediately under the subendothelial surface, the lesion in 
macroscopically visible as a yellow "fatty streak", but if the foam cell layers are 
deeper in the intima, the macroscopical appearance will be less defined (Stary 
1994). In type II lesions, also intimal smooth muscle cells contain lipid droplets. 
At any chance, most of the lipids are still contained within cells. 
A small subgroup of type II lesions are called type IIa: they raise in specific and 
predictable arteries with adaptive intimal thickenings, and they are called 
progression-prone or advanced-prone lesions. However, the majority of type II 
lesions belong to the type IIb group: they are also called "progression-resistant", 
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since their progression, when occurring, is slow, and occur only in subjects with 
very high serum lipoprotein levels (Stary 1994). 
On histopathological grounds, type IIa lesions contain more smooth muscle cells 
than type IIb, together with more extracellular matrix and macrophages, which 
constitute the adaptive thickening. 
 
 
Figure 3. Fatty streak. The macrophagic foam cells form stratified intimal layers. 
Haematoxylin-Eosin (left) and Trichrome stains (right); magnification 10x. 
 
 Type III lesions("intermediate lesions" or "preatheroma"). They are placed 
between type II and type IV lesions, and their morphological hallmark is the 
deposition of extracellular lipids, which replace the proteoglycan of the intimal 
matrix, but without a true lipid core. Type III lesions have different lipid content 
than types I and II: indeed they have more free cholesterol, triglycerids, 
sphingomyelin and lysolecithin (Katz 1976; Small 1988). 
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Figure 4. A type III lesion, characterized by the presence of extracellular lipids. 
Haematoxylin-Eosin (left) and Trichrome stains (right); magnification 10x. 
 
1.3.2 AHA classification of intimal lesions: advanced lesions 
The so-called advanced lesions are generally associated to a higher incidence of clinical 
manifestations. In these phases, the accumulation of lipids, matrix, and cellular elements 
cause a distortion of the arterial wall. The subsequent narrowing of the lumen may 
reveal itself both angiographically and clinically (Stary 1995). 
 Type IV lesions ("atheromas"). The extracellular lipid accumulation occupies a 
well-defined region of the intima, of variable extension, called lipid core. The 
atheroma does not show complications such as hemorrhages or surface defects, 
but the presence of the lipid core itself causes a distortion of the arterial walls 
and a narrowing of the lumen, which might cause stenosis and clinical 
manifestations: this is why type IV lesions are included among the advanced 
lesions. In younger subjects, atheromas initially appear in the same anatomical 
regions of eccentric arterial thickenings, thus they are considered adaptive 
changes. 
Most important (at least for the purposes of the present thesis) is that in the type 
IV lesions neoangiogenetic capillaries appear for the first time, initially located 
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in the peripheral margin of the lipid core ("shoulder"). A mild macrophagic 
infiltrate may follow the neovessels. 
 
 
Figure 5. A type IV lesion, or atheroma, characterized by a well-visible lipid core 
(arrow), without a formed fibrous cap yet. 
Haematoxylin-Eosin (left) and Trichrome stains (right); magnification 10x. 
 
 Type V lesions ("fibroatheromas"). In type V lesions a prominent fibrous cap 
appears over the lipid core, constituted by newly formed connective tissue with 
muscle cells rich in rough endoplasmic reticulum. The neovessels are more 
numerous and diffuse, and they also spread in the fibrous tissue. The type V 
lesions, which are also classified as type Va in 1995 classification, can be 
multilayered, due to the overlapping of multiple lipid cores and fibrous caps in 
time. 
Fibroatheromas, as type IV atheromas, can undergo to histological 
complications, and become type VI lesions, or can regress in two different ways. 
Lesions showing a massive calcification of the lipid core was defined as type Vb 
in the 1995 classification, and type VII in the more recent; lesions showing a 
prominent fibrotic involution of the lipid core was defined as type Vc in the 
1995 classification, and type VIII in the more recent. 
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Figure 6. Fibroatheroma (type Va). A thick fibrous cap (arrow) is present above the 
lipid core. Haematoxylin-Eosin (left) and Trichrome Stains (right); 
magnification 4x. 
 
 Type VI lesions ("complicated lesions"). The type VI lesions are defined as 
atheromatous lesions with features of type IV or V, but with (type VIa) erosion 
or ulcerations of the endothelial surface (type VIb), hemorrhage/hematoma or 
(type VIc) luminal thrombosis. 
All these complications represent the morphological base of the plaque 
vulnerability, and will be referred in the present thesis as histological 
complications. Evidences exist of a close relationship between plaque 
hemorrhage and neoangiogenesis (Mofidi 2001): newly formed vessels show a 
weak wall, without extracellular junctions (Sluimer 2009), and their growth in 
the lipid content of the plaque core can easily lead to rupture. Moreover, there is 
evidence that the neovessels of symptomatic plaques are larger and more 
irregular compared to the neovessels of asymptomatic plaques (McCarthy 1999). 
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Figure 7. An example of type VI plaque, characterized by multiple hemorrhagic foci 
(arrows). 
Haematoxylin-Eosin stain; magnification 4x. 
 
 
Figure 8. An example of type VI plaque, characterized by erosion of the endothelial 
surface (arrows). Haematoxylin-Eosin (left) and Trichrome Stains (right); 
magnification 4x. 
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Figure 9. An example of type VI plaque, with the presence of an organizing 
intraluminal thrombus. 
Haematoxylin-Eosin (left) and Trichrome Stains (right); magnification 4x. 
 
 
1.3.3 Modifications to the original classification 
In 2000 Stary modified his own previous classification of the atheromatous lesions, in 
order to better define the progression (or regression) of plaques from one type to another 
(Stary 2000). According to Stary, type IV and type V lesions can undergo to 
histological complications, becoming type VI lesions or they can regress into lesions 
with predominant calcifications or fibrosis; on the other hand, type VI lesions can 
regress in the same way as well. Complying with these possible different modifications 
of the plaques, the previous sub-classes Vb and Vc became types VII and VIII 
respectively. 
 Type VII lesions (calcified lesions). This type of atheromatous lesions replaced 
the type Vb of the old nomenclature. They are characterized by a core almost 
fully replaced by a massive deposition of calcification. 
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Figure 10. A heavily calcified uncomplicated plaque, classifiable as type VII (or Vb 
according to 1995 classification). The calcium deposits completely deform the vessel's 
architecture. 
Haematoxylin-Eosin (left) and Trichrome Stains (right); magnification 4x. 
 
 Type VIII lesions (fibrous lesions). It replaced the type Vc of the old 
nomenclature. The lipid core is completely replaced by collagen. 
 
 
Figure 11. A type VIII (or Vc according to 1995 classification) plaque. The lipid core is 
not visible, replaced by collagen. 
Haematoxylin-Eosin (left) and Trichrome Stains (right); magnification 4x. 
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The types VII and VIII plaques represent the two major ways of regressive involution to 
which a atheromatous plaque can undergo. This regression can involve either directly a 
type V uncomplicated lesion or a type VI lesion, according to the following pathway: 
 
 
Figure 12. Proposed pathway of progression from a plaque type to another. 
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1.4 PREVIOUS RESEARCH OF OUR GROUP 
 
1.4.1 Nestin and WT1 as markers of active neoangiogenesis 
Nestin is an embryonic intermediate filament protein expressed in neural and 
mesenchymal stem cells, and it was recently described by Wagner and colleagues to be 
expressed in a variety of progenitors cells (Wagner 2006). In that paper, the role of 
Nestin as an angiogenic marker, expressed in newly formed microvessels, was 
demonstrated in endothelial cells of newly forming blood vessels after myocardial 
infarction (Wagner 2006), but later it was demonstrated also in both tumoral and not-
tumoral neoangiogenesis (Ramasamy 2011). Afterwards numerous Nestin-positive 
microvessels were described also in tumoral neoangiogenesis, mainly in mouse models 
(Teranishi 2007; Ramasamy 2011). Moreover, a previous study showed that medial 
vascular smooth muscle cells in the developing arteries potently express Nestin, but its 
expression is abolished in adult arteries (Oikawa 2010). It is therefore believed that 
Nestin expression, representing an early endothelial differentiation or an endothelial 
progenitor phenotype, could be a reliable marker of “progenitor-committed” endothelial 
cells, or of a “young” endothelium, during active neoangiogenesis. 
The known transcription factors regulating Nestin gene expression are: Pou, Sox, TTF-1 
and WT1 (Wagner 2006; Pelizzoli 2008). The Wilms tumor suppressor (WT1) was 
originally described in the paediatric Wilms’ tumor of the kidney (or nephroblastoma), 
but its involvement has been demonstrated in a variety of other tumors and tumor cell 
lines (Hohenstein 2006; Wagner 2008). Some recent studies showed the involvement of 
WT1 as an activator of the Nestin gene (Hohenstein 2006), and the co-localization of 
WT1 and Nestin during the different development steps in embryogenesis (Wagner 
2006). 
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1.4.2 Physiology of vasa vasorum and neoangiogenesis in diseased arteries 
Vasa vasorum are small arteries present in the adventitia of the vessels of major calibre. 
The principal functions of vasa vasorum are nutrient and oxygen delivery to the deeper 
vascular layers and waste removal (Ritman 2007; Mulligan-Kehoe 2010). In the largest 
vessels the so-called first-order vasa vasorum take origin directly from other arteries 
and run longitudinally along the adventitia (Kwon 1998). The second-order vasa 
vasorum derive from a branching of the first-order vasa vasorum and reach the deeper 
adventitia and media layers. In animal models the application of microscopic computed 
tomography in healthy vessels demonstrated that vasa vasorum form a plexus around 
the adventitia, with generally a lower number of second-order vasa vasorum rather than 
first-order. This condition changes in pathological conditions, where a dramatically 
increase in second order vasa vasorum was observed (Kwon 1998). In diseased arteries 
the vessel wall hypoxia unleashes the neoangiogenesis starting from the adventitial vasa 
vasorum. In these pathological conditions vasa vasorum, and especially the second-
order vasa vasorum proliferate quickly, also regulated by local and circulating growth 
factors such as vascular endothelial growth factor and hypoxia inducible factor, among 
others (Moreno 2006). This neovasculogenic potential has been largely studied in the 
last decades, and the existence of endothelial progenitor cells (EPCs) within the layers 
of the larger vessels has been widely accepted, although their location, phenotype and 
roles in the vascular damage and angiogenesis are still debated (Zengin 2006; 
Pasquinelli 2007; Torsney 2011). Most authors agree that a population of progenitor 
cells is localized in the adventitia, characterized by positivity for different markers of 
vascular stem potential, such as CD34, c-Kit, CD105, Notch-1, SCA1, and KDR 
(Alessandri 2001; Hu 2004; Pfister 2005; Zengin 2006; Pasquinelli 2010; Leri 2011). 
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1.4.3 Nestin and WT1 expression in healthy vasa vasorum 
In the first study that we published during the PhD program, we performed a 
histological and immunohistochemical analysis of vasa vasorum in 20 not-diseased 
arteries from 16 healthy multiorgan donors (Vasuri 2012). Our aim was to verify Nestin 
and WT1 expression in endothelial cells of normal adult vasa vasorum, in order to 
localize and quantify these microvessels that could be responsible for 
neovascularization in diseased arteries. In these 20 specimens immunohistochemistry 
for CD34, CD31, Nestin and WT1 was performed manually and the microvessel 
“densities” of positivity were calculated for each antibody, dividing the vascular 
adventitia in 1-mm
2
 fields with an ocular micrometer in each slide. Double 
immunofluorescence was used to investigate Nestin and WT1 co-localization in vasa 
vasorum. 
As results, the mean positivity “densities” for CD31, CD34, Nestin and WT1 were 
13.63/mm
2
, 12.20/mm
2
, 8.90/mm
2
 and 7.98/mm
2
 respectively. Mean Nestin/CD31 and 
WT1/CD31 ratios were 0.69 and 0.63 respectively, which means that 69% and 63% of 
the CD31-positive neovessels also expressed Nestin and WT1 respectively. As 
expected, the Nestin:WT1 ratio was close to 1:1, as also confirmed by 
immunofluorescence, which indentified Nestin and WT1 coexpression in the same 
endothelial cells. 
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Figure 13 (reprinted from Vasuri 2012). On the left, schematic quantitative 
representation of CD31, CD34, Nestin and WT1 expression in healthy arteries, and 
their relationships. On the right, the immunohistochemical positivity of CD31, Nestin 
and WT1 in vasa vasorum. 
 
Finally, vasa vasorum <50 µm in diameter showed a higher percentage of Nestin/WT1-
positive cells than the larger vasa vasorum, especially in “hot spots”, characterized by 
several small-sized arteriolar vasa vasorum, often together with nerva vasorum. Our 
experience indicated that WT1 and Nestin colocalize with a 1:1 ratio in the vasa 
vasorum endothelium from adult healthy arteries. 
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Figure 14 (reprinted from Vasuri 2012). Schematic picture of vasa vasorum, and their 
different Nestin/WT1 phenotypes. 
 
1.4.4 Nestin and WT1 in neoangiogenesis of atheromatous plaques 
In the second step of our research, we performed a study on the expression of Nestin 
and WT1 in the neoangiogenetic component of the atheromatous plaques, in order to 
describe and quantify the protein and mRNA levels of WT1 and Nestin in the plaque 
neovessels and to investigate the role of neovessel phenotype in the occurrence of the 
histological complications correlated with plaque instability (Fittipaldi et al., under 
revision). For these purposes we prospectively evaluated 49 consecutive carotid 
endarterectomy specimens, collected the main histopathological characteristics 
(particularly the occurrence of histological complications) and carried out 
immunohistochemistry for CD34, Nestin and WT1; the density of positivity was 
evaluated for each marker in "regions of interest". RT-PCR was performed to assess 
Nestin and WT1 mRNA levels on the first 10 plaques and on 10 control arteries. 
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As results, the mean immunohistochemical densities of CD34, Nestin, and WT1-
positive structures were 41.88/mm
2
, 28.84/mm
2
 and 17.68/mm
2
 respectively. Among 
the CD34+ neovessels, 68% and 42% expressed Nestin and WT1 respectively, i.e., 
nearly 36% of the neovessels showed a Nestin+/WT1- phenotype. Furthermore, 
complicated plaques (n=30) showed significantly more CD34 and Nestin-positive 
vessels than uncomplicated plaques (n=13; P=0.045 and P=0.009), while WT1 was less 
increased (P=0.139). RT-PCR confirmed that WT1 gene expression was 3-fold lower 
than Nestin gene in plaques (p=0.001). we concluded that plaque neoangiogenesis 
shows both a Nestin+/WT1- and a Nestin+/WT1+ phenotype. The Nestin+/WT1- 
neovessels are significantly more represented in plaques with histological complication 
(hemorrhage above all). 
 
Figure 15 (reprinted from Fittipaldi, under revision). Different Nestin/WT1 phenotypes 
in complicated and uncomplicated atheromasic plaques.
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1.5 AIMS OF THE THESIS 
 
The aims of the present thesis are: 
1. To confirm our previous results on Nestin/WT1 phenotype in a larger series 
of carotid atheromatous plaques. 
Histopathological analysis and immunohistochemistry for CD34, Nestin and 
WT1 will be carried out on a series of 73 consecutive carotid plaques. The 
plaque morphology and the immunohistochemical densities of positivity will be 
correlated in order to confirm our previous data on Nestin+/WT1+ and 
Nestin+/WT1- phenotypes in plaque neoangiogenesis. 
 
2. To evaluate the relationship between the Nestin+/WT1- neoangiogenesis 
phenotype and the main histopathological plaque characteristics (especially 
complications). 
The Nestin+/WT1+ and Nestin+/WT1- phenotypes will be analyzed according 
to the separate atheromatous types (V, VI, VII, and VIII). Special attention will 
be paid to histological complications (hemorrhage, surface defects, thrombosis) 
that identify type VI plaques, and massive calcifications, that define class VIII 
(ex class Vb) plaques. 
 
3. To evaluate the relationship between the immunohistochemical and 
histopathological characteristics and the clinical instability of the plaques. 
The clinical data of the 73 patients who underwent endarterectomy will be 
collected, with focus on symptomatology (stroke and/or transient ischemic 
attack) and on the presence of brain lesions at computerized tomography. These 
data will be related to the plaque type and the neoangiogenesis phenotype.
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2. MATERIALS AND METHODS 
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2.1 PATIENTS SELECTION AND CLINICAL DATA 
 
2.1.1 Indications for endarterectomy 
According to the European Society for Vascular Surgery (ESVS) and the Society of 
Vascular Surgeons (SVS) recommendations (Hobson 2008; Liapis 2009), the patients 
were submitted to carotid endarterectomy (CEA) for either symptomatic carotid plaques 
≥50% or asymptomatic carotid stenosis ≥70%. Symptomatic carotid stenosis was 
defined as the occurrence of ipsilateral cerebral ischemic events (major or minor stroke, 
transient ischemic attack, or amaurosis fugax) in the last 6 months. 
 
2.1.2 Clinical data and follow-up 
For each patient the following clinical data were collected:  
1. Occurrence of symptoms related to the carotid disease, i.e. transient ischemic 
attack (TIA) and stroke. 
2. Evidence of brain focal lesions by means of CT. 
3. Association with chronic ischemic cardiopathy. 
4. Association with chronic obstructive broncopneumonia. 
5. Association with chronic renal failure. 
6. Concomitant therapy with acetylsalicylic acid (asa), oral anticoagulant, or 
statins. 
7. Percentage of carotid stenosis, and percentage of the eventual contralateral 
stenosis, if present. 
 
As follow-up, TIA, stroke, myocardial infarction, hematoma or death related to these 
causes were evaluated as patients poor outcome after endarterectomy.  
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2.2 HISTOPATHOLOGICAL ANALYSIS 
 
Endarterectomy specimens were sent to our Pathology Unit in formalin (Formaldehyde 
4%), from gross examination, which normally includes the description and the 
measurement of the specimen (carotid segment or carotid bifurcation, including the 
common, the inner and the outer branches), the description of all plaques and visible 
intimal thickenings, the eventual evidence of macroscopic erosions and thrombosis. 
Specimens were therefore cut in cross sections, and included in toto in one or two 
specimen blocks. 
 
 
Figure 16. An example of endarterectomy specimen. Note the deformation of the vessel 
wall architecture, and the endothelial irregularities. 
 
Blocks were routinely processed and paraffin embedded. From these formalix-fixed 
paraffin-embedded (FFPE) samples, 2 µm-thick slices were cut for routine 
histopathological diagnosis with Heamatoxylin-Eosin stain. The most representative 
sample was also stained with Trichrome stain, which briefly evidences the elastic fibers 
in red (fuchsin) and the collagen in green (Light Green). 
The histopathological routine analysis and the collection of the histopathological 
variables were performed by means of an Olympus
®
 BX50 microscope. For given 
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variable we used an Olympus
®
 ocular micrometer: one length unit of the micrometer is 
equal to 5 µm at 20x magnification, which means that an area of 100 x 100 units is 
equal to 0.25 mm
2
, and four are equal to 1-mm
2
.  
 
For each case, 14 histopathological features were collected as single variables: 
1. Maximum size of the fibrous cap, evaluated by means of the ocular micrometer. 
2. Minimum size of the fibrous cap, evaluated by means of the ocular micrometer. 
3. Extension of the lipid core, from one fourth to four fourth of the vessel section. 
4. Extension of calcifications, from one fourth to four fourth, then simplified in 
low-grade calcification (if absent or 1-2/4) and high-grade calcification (if 3-4/4) 
5. Amount and localization of the inflammatory infiltrate. The intraplaque flogosis 
was semi-quantified from 0 (absent) and 1+ (mild) to 2+ (moderate) and 3+ 
(severe). Flogosis localization was assessed as well, whether prevalently in the 
shoulder, in the fibrous cap, or diffuse throughout the section. 
6. Amount and localization of the neoangiogenesis. As for the flogosis, the 
intraplaque neoangiogenesis was semi-quantified in 0 (absent), 1+ (mild), 2+ 
(moderate) and 3+ (severe), with the same localizations as above. 
7. Minimum diameter of the plaque neovessels, evaluated by means of the ocular 
micrometer. 
8. Maximum diameter of the plaque neovessel, evaluated by means of the ocular 
micrometer. 
9. Evidence of "large and winding" neovessels, by Haematoxilin-Eosin or with 
CD34. 
10. Evidence of "dot-like" structures, exclusively by means of CD34. 
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11. Evidence of histopathological complications, which put the plaque into the AHA 
type VI. The complications were therefore sorted into three main groups, as 
follows: 
12. Hemorrhage, with or without fissurations. 
13. Thrombosis. 
14. Endothelial erosion or ulceration. 
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2.3 IMMUNOHISTOCHEMISTRY 
 
The monoclonal antibodies used in this study are listed in Table 1. 
 
Antibody Clone Manufacturer 
Nestin 10C2 (mouse IgG) Millipore 
WT1 6F-M2 (mouse IgG) Roche Ventana 
CD34 QBEnd/10 (mouse IgG) Roche Ventana 
Table 1. Technical characteristics of the antibodies used for immunohistochemistry. 
 
2.3.1 Manual procedure 
Immunohistochemistry for Nestin was performed manually; the first step consisted in 
the dewaxing of the histological slides by means of three baths in BioClear (Bio-Optica, 
Milan), 10 min each, followed by alcohol in decreasing dilution (100°, 96°, 70°) and 
rehydration with distilled water for 5 min. A citrate buffer chelating the bivalent ions, 
pH 6.0, was applied as antigen retrieval: slides are put in citrate buffer for four cycles 5 
min each, in a 750 W microwave. Endogenous peroxidases were blocked in a solution 
of 3% H2O2 in methanol for 10 min. After the antigen retreval and the peroxidases 
inhibition, slides were equilibrated in a TBS buffer (Tris Buffered Salin pH 7.6) 1x for 
10 min before the incubation with the primary antibody. 
Slides were incubated with the anti-Nestin primary antibody in a wet chamber at room 
temperature for 1 h, and therefore washed three times or 5 min each in TBS buffer. 
Finally, histological sections were incubated with the NovoLink Polymer Detection 
System (Leica Biosystems, Newcastle Ltd Balliol Business Park, West Benton Lane, 
Newcastle Upon Tyne NE12 8EW, United Kingdom) as follows: (1) a first incubation 
lasting 30 min in the Novocastra Post Primary Block reagent, used in order to imply the 
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penetration of the second polymeric reagent; (2) a second incubation (spaced out by a 5-
min bath in TBS), lasting 30 min, in NovoLink Polymer, which links mouse and rabbit 
immunoglobulins. 
Afterwards, sections were incubated in DAB chromogen 3’-3’ diaminobenzidine) for 10 
min. The staining reaction was blocked by means of distilled water for 5 min, and 
therefore the slides were counterstained with Heamatoxylin for 2 min, dehydrated with 
alcohol in increasing dilution (70°, 96°, 100°) and BioCLear, and then mounted with 
Eukitt (O.Kindler, Freiburg, Germany). 
 
2.3.2 Automatic procedure 
Immunohistochemistry for CD34 e WT1 was performed automatically, by means of 
Benchmark XT (Ventana Medical System), using the XT ultraView DAB v3 program. 
After the automatic dewaxing, the protocol included a pretreatment with the Cell 
Condition 1 Ventana (CC1), an EDTA buffer, pH 8.0, for 36 min at 95°C. Afterwards 
the slides were treated with an inhibitor at 37°C to avoid aspecific signals, and then 
washed. The primary antibodies were incubated at 37°C for 28 min (WT1) or 16 min 
(CD34). After the bath, the polymer and the chromogen (UV HRP UNIV MULT e UV 
DAB, Ventana Medical Systems), needed for the amplification of the antigen-antibody 
reaction, were added on the slides, followed by further reagents and baths in order to 
block the development reaction (UV DAB H2O2, UV COPPER). The last automatic step 
consists in the counterstaining with Haematoxilin II (Roche-Ventana Medical Systems); 
afterwards slides are dehydrated and mounted. 
 
2.3.3 Evaluation of the "density" of positivity with Immunohistochemistry 
The microvessel “density” per section was obtained by dividing the sum of all CD34-
positive vascular structures observed by the number of counted fields in the section of 
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the total areas analyzed in all fields. Together with the microvessel density, we 
identified specific Regions of Interest (ROI), characterized by a major density of CD34-
positive structures, and we counted the number of vascular structures expressing Nestin 
and WT1 in each ROI. Briefly, at 20x magnification we divided each ROI in 1-mm
2
 
fields, using a Olympus
®
 ocular micrometer (1 length unit = 5 µm, which means that an 
area of 100 x 100 units is equal to 0.25 mm
2
). 
With these data, we could therefore evaluate the following variables: 
 The number of fields, positive structures and density of positivity for CD34, 
Nestin, WT1. 
 The ratio between the densities of positivity of Nestin/CD34: this value 
represents how many CD34-positive neovessels concomitantly express Nestin. 
 The ratio between the densities of positivity of WT1/CD34: this value represents 
how many CD34-positive neovessels concomitantly express WT1. 
 The ratio between the densities of positivity of WT1/Nestin: this value 
represents how many Nestin -positive neovessels concomitantly express WT1. 
 
Moreover, as for the previous analysis on diseased carotid arteries, the presence of "dot-
like" structures and "large winding" neovessels was assessed. The former represent 
small neovessels with no visible lumen, generally packed in groups; the latter are 
neovessel with winding and irregular lumen, of large diameter, resembling the immature 
neovessel of malignant tumors (Sluimer 2009). The positivity for the three antibodies by 
the "dot-like" and "large and winding" structures was recorded as well. 
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2.4 RT-PCR 
 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for the products of the 
Nestin and WT1 genes was carried out on 5 type V and on 5 type VI plaques, in order to 
evaluate the different expression in complicated and uncomplicated carotid plaques. 
A pool composed by 5 healthy arteries was used as control. Healthy arteries were kindly 
provided by the Cardiovascular Tissue Bank of S.Orsola-Malpighi Hospital of Bologna. 
 
2.4.1 Trizol RNA extraction 
Tissues were homogenized with an Ultraturax and incubated with 800 ul of Trizol 
reagent (TRIreagent, Ambion Cat #AM9738) for 5 min at RT. RNA extraction with 
Trizol was performed following manufacturer instructions. Mainly chloroform was 
added to the sample (0.2 ml: 1 ml trizol). The sample are shacked vigorously for 15 
seconds and incubated for 2 min at room temperature, left for 2 min in ice, centrifuged 
at 12000g, 15 min at 4°C. The RNA phase was gently collected in a new Eppendorf and 
500 µl of isopropyl alcohol was added with 5 µl of glicogen (2µg/µl). To allow RNA 
precipitation, samples were incubated at room temperature for 10 min and centrifuged at 
12000g for 10 min, 4°C. Surnatant was discarded and RNA pellet was washed with 
75% ice ethanol, then centrifuged at 7500g for 5 min and air dried for 20 min. Finally 
RNA was eluted in 15 µl RNAse free-water, heated at 65°C for 5 min in order to 
denature RNA and to inactivate RNases. RNA quality and concentration were measured 
by using an ND-1000 spectrophotometer (NanoDrop, Fisher Thermo, Wilmington, DE, 
USA). To compare efficiency of RNA extraction from FFPE we used as a positive 
control RNA extracted from fresh tissue. 
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2.4.2 RT-PCR analysis 
Reverse transcription assay was performed using 2.0 µg of starting total RNA quantity 
per 25 µl of mix, following the manufacturer’s protocol (High capacity cDNA Archive 
kit, Applied Biosystem). The cDNA was stored at -20°C until RT-PCR was performed. 
RT-PCR was carried out following MasterMix TaqMan
®
 Protocol (TaqMan Univ PCR 
MasterMix, Applied Biosystems). Four µl of neat cDNA was amplified using specific 
probes for WT1 (NC_000011.9), Nestin (NC_000001.10) and GUSB (NM_000181.3) 
in the RT-PCR mix (TaqMan
®
 Gene Expression Assay, Applied Biosystems, respective 
ID assay: Hs01103751_m1, Hs04187831_g1, Hs00939627_m1). Reactions were run on 
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Cycling 
conditions were as follows: 10 min at 95°C, 50 cycles at 95°C for 15 s and 60°C for 60 
sec. Each assay was carried out in triplicate and the transcription level was normalized 
using βActin as a reference gene. 
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2.5 STATISTICAL ANALYSIS 
 
All statistical analyses in the present study were carried out with SPSS
®
 software for 
Windows, version 20. 
All continuous variables are expressed as means, standard deviations and ranges; all 
categorical variables (both nominal and ordinal) are expressed as number of cases and 
percentages. 
According to the kind of independent and dependent variable, the following statistical 
tests were applied: 
 The Spearman's test was used to compare continuous variables. It was also 
applied in all cases to evaluate the Spearman coefficient.  
 The chi-square test was used to compare categorical variables. 
 The Mann-Whitney test was used to compare a categorical dichotomous 
independent variable (e.g. type V versus type VI plaques, or calcified versus not-
calcified plaques) with continuous dependent variables. 
 The Kruskal Wallis test was used to compare a categorical ordinal independent 
variable (e.g. the four different kinds of plaques) with continuous dependent 
variables. 
As for RT-PCR analysis, a threshold at 0.2 was selected in order to be in the 
exponential phase. The expression values for atheromatous carotid plaques are 
presented as fold expression in relation to healthy arteries; the actual values were 
calculated using the 2−ΔΔCT equation (Yuan et al. 2006), where ΔΔCT = [CT Target − 
CT βActin](atheromatous sample) − [CT Target − CT βActin] (healthy sample). Due to 
the technical difficulty to detect WT1 gene expression, Human immortalised 
myelogenous leukemia line cell line (K562) were used as a positive control (Yuan et al. 
2006).
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3. RESULTS 
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3.1 PATIENTS AND CLINICAL DATA 
 
Seventy-three patients were finally enrolled, 53 (72.6%) males and 20 (27.4%) females, 
mean age at the time of surgery 70.8±8.7 years (range 42-86). 
 
 Number of 
patients 
Percentage 
Stroke 11 15.1% 
TIA 18 24.6% 
TC positivity 25 34.2% 
Hypertension 65 89.0% 
Dyslipidemia 51 69.9% 
Diabetes 20 27.4% 
Smoke 6 8.5% 
Chronic Ischemic Cardiopathy 25 34.2% 
BPCO 4 5.5% 
Chronic Renal Failure 4 5.5% 
Aspirin use 64 87.7% 
Statins use 42 57.5% 
Table 2. Summary of the main clinical characteristics of the 73 patients. 
 
Of note, 11 (15.1%) patients had a stroke as clinical presentation, and 18 (24.6%) a 
transient ischemic attack. So a total of 29 (39.7%) plaques were symptomatic. 
 
At follow-up, 2 patients had a TIA, 2 had a stroke, and 3 more patients had a 
myocardial infarction. Two patients died at follow-up, one with stroke and one in 
absence of post-surgical acute comorbidities. Due to the low number of events at 
follow-up, no survival studies will be performed further. 
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3.2 HISTOPATHOLOGICAL ANALYSIS 
 
Here are listed the rough results about the morphological variables that were analyzed 
separately in the 73 plaques: 
1. Maximum cap size: 1132.8±485.6 µm (range 120-2500) 
 
2. Minimum cap size: 284.3±199.7 µm (range 40-1125) 
 
3. Extension of the lipid core:  not evident in 8 (11.0%) cases 
    1/4 in 16 (21.9%) 
    2/4 in 18 (24.7%) 
    3/4 in 23 (31.4%) 
    4/4 in 8 (11.0%) 
 
4.  Calcifications:   absent in 11 (15.1%) cases 
    1/4 in 21 (28.8%) 
    2/4 in 20 (27.4%) 
    3/4 in 16 (21.9%) 
    4/4 in 5 (6.8%) 
According to this semi-quantitative assessment of the calcification extent 
(expressed as fourths of the lumen occupied by calcification), the plaques were 
therefore subdivided in two major groups: low-grade calcification (which 
included the plaques with up to 2/4 of extension) and high-grade calcification 
(including plaques with calcifications in 3/4 and 4/4 of the wall circumference). 
In our series, 52 (71.2%) plaques showed low-grade calcifications, and 21 
(28.8%) high-grade calcifications. 
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It should be remembered that the high-grade calcification does not imply a 
placement in the AHA type VII, since calcified plaques with histological 
complications were considered as type VI. 
 
5. Inflammation:   absent in 4 (5.5%) cases 
    mild in 10 (13.7%) 
    moderate in 20 (27.4%) 
    severe in 39 (53.4%) 
As expected, the inflammatory infiltrate was mainly composed by monocytes, 
macrophages (as "foam cells" in proximity if the lipid core) and lymphocytes; 
the presence of granulocytes was rarely observed. The flogosis was localized in 
the plaque shoulder in 14 (19.2%) cases, within the cap in 19 (26.0%), intra-
plaque in 11 (15.1%), and in was diffuse in all artery wall in 25 (34.2%). In 4 
cases, 5.5%, flogosis localization was not evaluable. 
 
6. Neoangiogenesis (semi-quantitative assessment): 
    absent in 2 (2.7%) cases 
    mild in 19 (26.0%) 
    moderate in 21 (28.8%) 
    severe in 31 (42.5%) 
Neoangiogenesis was localized in the plaque shoulder in 19 (26.0%) cases, 
within the cap in 17 (23.3%), intra-plaque in 13 (17.8%), and in was diffuse in 
21 (28.8%). One (1.4%) case was not evaluable. 
 
7. Minimum diameter of the plaque neovessels: 15.3±24.0 µm (range 1-125) 
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8. Maximum diameter of the plaque neovessel: 224.1±210.4 µm (range 50-1500) 
 
9. Evidence of large and winding neovessels: this kind of neovessel, very 
resembling the neovessel of tumoral neoangiogenesis, was recorded in 32 
(43.8%) of cases. 
 
10. Evidence of "dot-like" structures: they were seen in 31 (42.5%) plaques. 
 
11. Histopathological complications: the presence of at least one histopathological 
complication, which define the type VI plaque of the AHA classification, was 
recorded in 52 (71.2%) plaques. In particular, plaque hemorrhage/fissuration 
was present in 41 (56.1%), endothelial erosion or ulceration in 22 (30.1%), and 
thrombosis in 4 (5.5%) cases. 
 
  
Results 
 
44 
 
3.3 IMMUNOHISTOCHEMISTRY 
 
IHC for the three antibodies was evaluated in 71 cases, i.e. excluding the two cases with 
no visible neoangiogenesis at CD34. We initially evaluated the intraplaque 
neoangiogenesis by CD34, and we assessed specific areas named region of interest 
(ROI). ROI were defined as areas with CD34-positive neoangiogenesis, and the 
microvessel counting was performed for each slide in ROI, by means of an ocular 
micrometer. The Nestin- and WT1-positive vessels were counted in the same ROI 
where CD34 was evaluated. 
The microvessel “density” of each antibody was obtained by dividing the sum of all 
positive structures observed in ROI by the number of the counted fields expressed in 
mm
2
 (number of positive vessels/mm
2
). 
 
 Min Max Mean St. Dev. 
CD34 evaluated fields 1 33 12.4 7.3 
CD34+ structures 11 391 130.7 91.4 
CD34 density 3.5 22.1 10.1 3.9 
Nestin evaluated fields 1 34 10.5 6.3 
Nestin+ structures 7 296 73.0 59.4 
Nestin density 1.4 18.5 6.8 3.7 
WT1 evaluated fields 1 37 11.3 6.8 
WT1+ structures 4 300 54.7 54.8 
WT1 density 0.8 18.8 4.5 3.0 
Nestin/CD34 ratio 0.2 1.5 0.7 0.2 
WT1/CD34 ratio 0.1 1.0 0.4 0.2 
WT1/Nestin ratio 0.2 1.8 0.7 0.3 
Table 3. IHC results for each separate variable. 
 
 
Results 
 
45 
 
 
Figure 17. Immunohistochemistry for Nestin (on the left) and WT1 (on the right). Not 
all Nestin+ vascular structures also expressed WT1 (arrow). 
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3.4 RT-PCR 
The total mean extracted mRNA from healthy tissue, type V and type VI plaques was 
8764 ng, 5069.4 ng and 2172 ng respectively. The mean CT values of endogenous 
control GUSB were 36.28±0.21 in healthy tissue, 31.36±0.32 in type V plaques and 
34.20±0.22 in type VI plaques. Mean CT for tested gene Nestin were 33.04±0.06 in 
healthy tissue, 32.37±0.12 in type V plaques and 34.21±0.30 in type VI plaques. Mean 
CT for tested gene WT1 were 41.99±1.10 in healthy tissue, 36.61±1.20 in type V 
plaques and 45.07±1.15 in type VI plaques. ΔΔCT Nestin and ΔΔCT WT1 were 
significantly different from 0 (P=0.0001 and P=0.0006) thus the null hypothesis was 
rejected, which indicated a change in Nestin and WT1 gene expression between healthy, 
type V and type VI plaques. In type V and type VI plaques, the mean ΔΔCT Nestin was 
respectively 4.25 and 3.25, and the mean ΔΔCT WT1 was 2.54 and 5.16. This 
corresponds to 2^-(ΔΔCT) of 0.05 
for nestin gene expression in type 
V plaques and 0.11 in type VI 
plaques. This corresponds to 2^-
(ΔΔCT) of 0.17 for WT1 gene 
expression in type V plaques and 
0.03 in type VI plaques. The type 
VI plaques showed a 2-fold 
expression increase for Nestin 
gene and a 5-fold expression decrease for WT1 gene (compared to type V plaques). 
Thus, in complicated plaques Nestin expression increases while WT1 gene expression 
decreases (see Figure 18). 
  
Figure 18. 
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3.5 CORRELATIONS AMONG MORPHOLOGICAL VARIABLES 
 
At cross-correlation among the morphological variables, the mean maximum size of the 
plaque cap was significantly related with the amount of neoangiogenesis (P=0.006, 
Spearman coefficient 0.325). in particular, the mean maximum cap size was 
974.63±402.75 µm in plaques with low neoangiogenesis (1+/2+) and 1364.29±510.74 
µm in plaques with high neoangiogenesis (3+/4+). 
The extension of lipidic core was correlated with flogosis (P<0.001, Spearman 
coefficient 0.464), and intra-plaque hemorrhage (P=0.025, chi-square test, Spearman 
coefficient 0.339), since 33/40 plaques with hemorrhage had core extension ≥2+. 
Moreover, the core extension was inversely correlated with calcifications (P=0.005, chi-
square test, Spearman coefficient -0.324). In particular, 13/20 calcified plaques had 0/1+ 
of lipid core extension, versus 10/53 of the others. 
Finally, the plaques with massive calcifications (3+/4+) were characterized by a lower 
flogosis (P=0.004, Spearman coefficient -0.332) than other plaques. 
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3.6 CORRELATIONS BETWEEN IMMUNOHISTOCHEMISTRY AND 
MORPHOLOGY 
 
As expected, the densities of positivity of the three antibodies significantly correlated 
each others at P<0.001 (Spearman coefficients: CD34-Nestin 0.803; CD34-WT1 0.588; 
Nestin-WT1 0.669). 
 
The correlations of the immunohistochemical densities of the three antibodies with the 
plaque morphological variables are shown below: 
 CD34 (Table 4). It correlated with the lipid core extension (P=0.05, Spearman 
coefficient 0.234), the flogosis (P=0.002, Spearman coefficient 0.353), and it 
was inversely correlated with the amount of calcifications (P<0.001, Mann-
Whitney test, Spearman coefficient -0.322). Notably, the density of CD34 did 
not correlate with the occurrence of histological complications (P=0.111, Mann-
Whitney test, Spearman coefficient 0.189). 
 
 Not-calcified 
plaques 
Calcified plaques Complicated 
plaques 
Uncomplicated 
plaques 
CD34 density 11.19±3.84 7.52±3.09 10.68±3.79 8.99±4.13 
Mann-Whitney P<0.001 P=0.111 
Table 4. 
 
 Nestin (Table 5). The density of Nestin-positive neovessels was correlated with 
flogosis (P=0.005, Spearman coefficient 0.327), and inversely correlated with 
the occurrence of calcifications (P<0.001, Mann-Whitney test, Spearman 
coefficient -0.280). Unlike CD34, Nestin density correlated with the occurrence 
of histological complications (P=0.015, Mann-Whitney test, Spearman 
coefficient 0.293). 
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 Not-calcified 
plaques 
Calcified plaques Complicated 
plaques 
Uncomplicated 
plaques 
Nestin density 7.69±3.77 4.59±2.31 7.45±3.71 5.31±3.09 
Mann-Whitney P<0.001 P=0.015 
Table 5. 
 
 WT1 (Table 6). It correlated with flogosis (P<0.029, Spearman coefficient 
0.259), the occurrence of histological complications (P<0.033, Mann-Whitney 
test, Spearman coefficient -0.263), and it was inversely correlated with the 
amount of the calcifications (P=0.020, Mann-Whitney test, Spearman coefficient 
-0.280). 
 
 Not-calcified 
plaques 
Calcified plaques Complicated 
plaques 
Uncomplicated 
plaques 
WT1 density 4.99±3.31 3.16±1.64 4.88±3.19 3.45±2.43 
Mann-Whitney P=0.020 P=0.033 
Table 6. 
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3.7 IMMUNOHISTOCHEMICAL PROFILES OF THE DIFFERENT PLAQUE 
TYPES 
 
3.7.1 Complicated plaques 
In our series, the plaques with histological complications, classified as type VI 
according to AHA, were characterized by a larger extension of the lipid core (P=0.029, 
Spearman coefficient 0.260) and showed a slightly thinner fibrous cap P=0.074, 
Spearman coefficient -0.217) than uncomplicated plaques. 
At immunohistochemistry, as stated previously, the density of CD34-positive neovessel 
was not correlated with histological complications (P=0.111), while the density of both 
Nestin and WT1 was (P=0.015 and P=0.033 respectively). This is an important results, 
since it confirms our previous results, i.e. that it is not the amount of the sole 
neoangiogenesis to characterize type VI plaques, but the amount of the Nestin-positive 
neoangiogenesis. Notably, in this enlarged series, also WT1 is correlated with intra-
plaque complications (even if with a lower significance), while in our previous results it 
did not. 
 
3.7.2 Calcified plaques 
Twenty-one (28.8%) plaques showed extensive calcifications (3+/4+) in our series. 
Among these, 13 cases (61.9% of the calcified plaques) concomitantly showed one or 
more histological complications, and were therefore classified as type VI plaques 
according to AHA. In these cases, hemorrhage or fissuration were recorded in 11 cases, 
thrombosis in 3 cases, and defects in the endothelial surface in 5. The remaining 8 cases 
(38.1% of the calcified plaques) did not show histological complications, and they were 
classified as type VII according to AHA (Stary 2000), equivalent to the type Vb of the 
previous classification (Stary 1995). 
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Interestingly, the incidence of histological complications did not differ significantly 
between calcified and not-calcified plaques (P=0.167, Spearman coefficient -0.117). 
Moreover, at histopathology, calcified plaques showed significantly less flogosis 
(P=0.002, Mann-Whitney test, Spearman coefficient -0.332) than not-calcified plaques. 
At immunohistochemistry, as stated above, the densities of positivity of all three 
antibodies were less represented in the calcified plaques.  
 
 
Figure 19. Two examples of calcified atheromatous plaques. The low quality of the 
slides is due to the objective difficulties in processing and cutting calcified tissue. 
Magnification 4x. 
 
3.7.3 The influence of calcifications and neoangiogenesis on intra-plaque 
complications 
From our immunohistochemical results, it seems that the calcified plaques have a minor 
amount of flogosis and CD34-positive neovessels, but with the same incidence of 
histological complications, compared to the other plaques. 
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If we exclude the 21 calcified cases from the series, we can notice that the correlation 
between neoangiogenesis and complications becomes more important. 
 
Table 7. Statistical significance (Mann-Whitney test) in the morphophenotypical 
differences between type VI and other plaques, in all cases an in not-calcified cases 
only. 
 
In "classic" not-calcified plaques, the thickness of the fibrous cap and the extension of 
the core become more significant between calcified and not-calcified plaques, as well as 
all immunohistochemical markers of neoangiogenesis. In particular, CD34 density is 
significantly higher in "classic" plaques than in calcified plaques in the onset of intra-
plaque complications. 
 
 
 
 Types V-VIII 
(N=13) 
Type VII    
(N=8) 
Type VI not-
calc (N=39) 
Type VI calc 
(N=13) 
Sig. (K W) 
Mean min 
cap 
382.5 328.8 249.1 284.2 P=0.826 
Mean max 
cap 
1187.5 952.5 1145.1 1132.8 P=0.215 
Mean core 2.0 1.0 2.5 2.1 P=0.014 
Flogosis 2.5 1.1 1.2 2.3 P=0.005 
Mean neoang. 2.2 1.5 2.4 2.2 P=0.156 
CD34 10.1 6.4 11.6 10.1 P=0.002 
Nestin 5.9 3.8 8.3 6.8 P=0.001 
WT1 3.7 2.9 5.4 4.5 P=0.022 
Symptoms 3 (23.1%) 1 (12.5%) 22 (56.4%) 3 (23.1%) P=0.018* 
CT positivity 4 (57.1%) 1 (25.0%) 18 (62.1%) 2 (20.0%) P=0.092* 
Table 8. Immunomorphological differences among plaques sorted by AHA type and 
calcification. 
K W: Kruskal Wallis test. *chi-square test. CT data are available for 50 cases. 
 
 Cap Core CD34 Nestin WT1 
All cases P=0.074 P=0.029 P=0.114 P=0.014 P=0.029 
Not-calcified cases P=0.048 P=0.012 P=0.026 P=0.002 P=0.011 
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Figure 20. Progression/regression pathways among different plaque types, and their 
relative changes in neoangiogenesis phenotype and clinical presentations according to 
our results. 
 
Figure 20 summarizes the relationship among the different plaque that we found in the 
present study. While no differences seem to exist between type V and type VIII 
(fibrotic) plaques, in type VI (complicated) plaques the Nestin-positive neoangiogenesis 
increases, as well as the incidence of symptoms and focal lesions at CT, as expected. 
The type VII (uncomplicated) calcified plaques show sensibly lower CD34-positive and 
Nestin-positive neoangiogenesis, and very few symptomatic cases, confirming that they 
represent a regressed kind of plaque. Conversely, the calcified complicated plaques 
show a CD34-positive and Nestin-positive neoangiogenesis comparable to the 
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neoangiogenesis of type VI not-calcified plaques, and therefore higher than type VII, 
but with an incidence of symptomatic cases similar to uncomplicated type VII plaques. 
This latter kind of plaque shares the same histopathological complications and Nestin-
positive neoangiogenesis of "classic" type VI plaques, but its clinical presentation is 
comparable to type VII plaques. 
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3.8 CORRELATIONS AMONG MORPHOLOGICAL PLAQUE TYPES, 
NEOVESSEL PHENOTYPES AND CLINICAL DATA 
 
3.8.1 Histological complications correlate with symptoms 
As expected, the plaques of AHA type VI had a significantly higher incidence of 
symptoms (stroke or transient ischemic attack) than the plaques of types V, VII and VIII 
(P=0.026, chi-square test, Spearman coefficient 0.256), since 25 out of 29 (86.2%) 
patients with symptoms had type VI plaques, versus 27 out of 44 (61.4%) patients 
without symptoms. 
In our series, AHA type VI did not correlate with the occurrence of focal lesions at 
Computed Tomography (P=0.500, chi-square test). 
 
3.8.2 Calcified plaques have less symptoms and brain lesions regardless the 
histological complications 
Among the 21 patients with calcified plaques, only 4 (19.0%) had symptoms at the 
onset, regardless the occurrence of histological complications, versus 25 out of 52 
(48.1%) not-calcified plaques (P=0.019, chi-square test, Spearman coefficient -0.229). 
Data about brain Computed Tomography were available in 50 cases, 14 with calcified 
plaques ad 36 not-calcified plaques. Focal brain lesions were detected in 3 out of 14 
(21.4%) patients with calcified plaques and 22 out of 36 (61.1%) patients with not-
calcified plaques. This difference was significant as well (P=0.013, chi-square test, 
Spearman coefficient -0.231). 
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3.9 THE CALCIFIED PLAQUES IN THE FEMALE PATIENTS 
 
Only 3 (15.0%) of the 20 female patients in our study were symptomatic. Notably, all 3 
had type VI atheromatous lesions. Nine had uncomplicated and asymptomatic plaques, 
which is the 45.0% of female patients, a percentage sensibly lower than in males 
(15.1%). Twenty-seven (50.9%) out of 53 male patients were asymptomatic and 26 
(49.1%) showed symptoms: in any case, the most represented type of atheromatous 
lesions in males was the type VI not-calcified plaque. 
 
The female sex is likely to represent a protective factor, since it implies a lower 
incidence of type VI plaques (P=0.044, chi-square test) and symptoms (P=0.007) than 
male patients. This seems to be related to the higher incidence of calcified plaques 
(P=0.017). 
 
 
 Type VI 
plaques 
Calcified 
plaques 
Symptoms 
Females  (N=20) 11 (55.0%) 10 (50.0%) 3  (15.0%) 
Males     (N=53) 41 (77.4%) 11 (20.8%) 26 (49.1%) 
Sig. (chi-square) P=0.058 P=0.017 P=0.007 
Table 9. Different incidence in intra-plaque complications and calcifications between 
male and female patients. 
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  sex Total 
male female 
asymptomatic 
Not-VI 
calcif 
V-VIII 6 4 10 
VII 2 5 7 
Total 8 (15.1%) 9 (45.0%) 17 
VI 
calcif 
No 13 4 17 
Yes 6 4 10 
Total 19 (35.8%) 8 (40.0%) 27 
  
 27 (50.9%) m 17 (85.0%) f  
 asymptom asymptom  
symptomatic 
Not-VI 
calcif 
V-VIII 3  3 
VII 1  1 
Total 4 (7.5%) 0 (0.0%) 4 
VI 
calcif 
No 20 2 22 
Yes 2 1 3 
Total 22 (41.5%) 3 (15.0%) 25 
  
 26 (49.1%) m 3 (15.0%) f  
 symptom symptom  
Total 
Not-VI 
calcif 
V-VIII 9 4 13 
VII 3 5 8 
Total 12 (22.6%) 9 (45.0%) 21 
VI 
calcif 
No 33 6 39 
Yes 8 5 13 
Total 41 (77.4%) 11 (55.0%) 52 
 
     
Patients 53 m 20 f 73 total 
 
 
  High prevalence of uncomplicated plaques in asymptomatic females 
  High prevalence of not-calcified complicated plaques in males 
  Higher incidence of symptomatic plaques in males than females 
 
Table 10. Multivariable cross-table describing our series, with special emphasis on sex 
differences.
 
 
 
Discussion 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
4. DISCUSSION 
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The aims of the present thesis were: (1) to confirm our previous results on Nestin/WT1 
phenotype in a larger series of carotid atheromatous plaques, (2) to evaluate the 
relationship between the Nestin+/WT1- neoangiogenesis phenotype and the main 
histopathological plaque characteristics, and (3) to evaluate the relationship between the 
immunohistochemical and histopathological characteristics and the clinical instability of 
the plaques. 
On an enlarged consecutive series of 73 carotid endarterectomy specimens, we could 
confirm our previous results on the different Nestin/WT phenotypes in carotid plaques, 
as well as some consolidated data present in the literature. 
 
At morphology, our results confirm the main features characterizing the vulnerable 
plaques: the extension of lipidic core was correlated with flogosis and intra-plaque 
hemorrhage, and the maximum size of the plaque cap was significantly related with the 
amount of neoangiogenesis. This confirms that the vulnerable plaque (with hemorrhage) 
is generally characterized by a large lipid core, flogosis, and a neoangiogenesis which is 
commonly visible with Haematoxylin-Eosin stain by an expert eye. 
At immunohistochemistry, about 70% of the intra-plaque neovessels expressed Nestin, 
and about 40% expressed WT1, with a mean WT1/Nestin ratio of 0.7. Consequently we 
can confirm that the Nestin+/WT1- phenotype was the more represented in the carotid 
atheromatous lesion, and that this phenotype correlated with the occurrence of intra-
plaque histopathological complications (which put the plaque in the type VI according 
to AHA). The main noteworthy difference that we found in this enlarged series 
compared to our previous results it is that also WT1 positively correlates with the intra-
plaque complications. In fact, in our preliminary study (Fittipaldi et al. under revision) 
WT1 was not significantly different between type VI and not-type VI plaques, while in 
our 73 patients both Nestin and WT1 were significantly increased. It is comprehensible 
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that a quote of Nestin+/WT1+ neovessels increases together with the more represented 
Nestin+/WT1- neovessels: at any chance, the lower statistical significance together with 
the fact that this data emerged only with a bigger series may indicate that this 
Nestin+/WT1+ portion is less represented. 
 
In our opinion, the most noteworthy result that emerged from the present study is the 
particular clinical and pathological profile characterizing the calcified plaques. 
The calcification of the atheromatous plaque was historically considered as a passive, 
degenerative process, and only recently it has begun to be studied, especially in aorta 
and coronary vessels. Most individual aged more than 60 years have progressively 
enlarging deposits of calcium in their major arteries, generally starting from the 
coronary arteries (Allison 2004). The severity and extent of mineralization reflect the 
atherosclerotic plaque burden and strongly predict cardiovascular morbidity and 
mortality (Sangiorgi 1998; Vliegenthart 2005): in a relatively recent study, no patients 
were found to have calcifications confined only to the coronary or carotid beds (Allison 
2004). The extent of calcification is associated with worse prognosis, albeit the real 
impact of calcification within a specific lesion remains unclear (Huang 2001). For 
example, in the coronary vessels small calcium depositions increase the probability of 
atherosclerotic plaque rupture, especially on their edges, while with individual, large 
calcification foci such risk may even decrease (Huang 2001; Vengrenyuk 2006). In a 
study on 10 stables and 10 ruptured coronary artery post-mortem specimens, 
calcifications did not significantly affect the stability of the atheroma, in contrast with 
the significant reduction in stability associated with lipids: removing the calcifications 
led to a statistically insignificant change in stress (Huang 2001). Anyway, vascular 
calcification is considered a worsening factor, probably due to the association with the 
general risk factors: a study by Iribarren et al (2000) found that aortic arch calcification 
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was associated with coronary heart disease risk both in men and women. Thus aortic 
arch calcification may reflect the general burden of disease or be a marker of more 
aggressive disease. 
Vascular calcification risk factors are similar to those of atherosclerosis: 
hypertriglyceridemia, increased LDL, decreased HDL, obesity, hypertension (Polhe 
2001). In particular, hypertension in men showed a odd ratio of 3.2 in the carotids, 3.9 
in coronaries and 2.7 in proximal aorta (Allison 2004). 
As for the pathogenesis, vascular calcification is now recognized as a pathobiological 
process sharing many features with embryonic bone formation (Demer 2008). Vascular 
cell differentiation responds to microenvironmental and mechanical cues, since 
substrates of great stiffness, such as fibronectin, promote osteochondrogenic 
differentiation, whereas distensible substrates, such as laminin, promote smooth muscle 
or adipogenic differentiation (Yip 2009). The so-called biomineralization process begins 
from the crystallization nucleators, which trigger the formation of a primary crystal 
nucleus, together with the removal of the mineralization inhibitors (ANK, nucleotide 
pyrophosphatase, matrix Gla protein). The extracellular matrix vesicles contain deposits 
of calcium, alkaline phosphatase (ALP) and pyrophosphatase, among others, which 
increase the inorganic phosphates in the vesicles, at least in mouse models (Anderson 
2004). They also stimulate the production of osteopontin, another nucleation inhibitor 
(Speer 2002). 
During the vessel calcification there are processes similar to those in the bone 
biomineralization. In depositions in both tunica interna and media of the vessel wall, 
matrix vesicles have been identified (Tanimura 1983). 
Post-mortem studies have shown that vessel wall may contain a typical bone, cartilage 
or adipose tissue, with bone as the predominating type of metaplasia (10-15% of 
samples), appearing in various morphological forms, from amorphous calcium deposits 
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to mature bone tissue (Karwowski 2012). Another recent theory (Pal 2011) postulated 
that the osteochondrogenic cells may derive from circulating progenitor cells (probably 
derived from the bone marrow, according to Sata 2005). These cells migrate and 
proliferate in the diseased artery as a response to different cytokines such as SDF-1α. 
Other cytokines like PDGF and VEGF, produced by platelet activation after the loss of 
endothelial integrity, are involved (Roberts 2005). 
Histologically, arterial calcifications can be classified in (1a) calcifications of the tunica 
intima, especially related to atherosclerosis and, (1b) calcifications of the tunica media, 
unrelated to atherosclerosis (Monckeberg's type) (Karwowski 2012). The latter group 
embraces also the calcific uremic arteriopathy. Etiologically, the calcifications can be 
divided into metastatic and dystrophic (Karwowski 2012). The first type occurs when 
the calcium and phosphates increase (hyperthyroidism, neoplasm, vitamin D overdose, 
etc.), the latter occurs with normal mineral concentrations in damaged or necrotic 
tissues, as it is the case of atherosclerosis, but also neoplasm, tuberculosis, parasitosis, 
etc. (Demer 2008). 
The intimal (1a) atherosclerotic calcifications are the most common form of 
calcification. Calcium accumulation is initiated by an increase in the plaque of modified 
lipids, pro-inflammatory cytokines, phosphate and lipoprotein complexes, as well as 
foci of necrosis (Demer 2008; Karwowski 2012). In vitro studies have shown that pro-
inflammatory cytokines, oxidized LDL or other macrophage release products promote 
osteogenesis and the calcium accumulation (Tintut 1998; Proudfoot 2002; Tintut 2002), 
while some studies (but not all) correlated the vascular calcification with the so-called 
"cholesterol-years" (Schmidt 1996) and with inflammation in vivo (Aikawa 2007). In 
vitro, the calcifying vascular cells (CVC, a subpopulation of smooth muscle cells with 
osteoblastic characteristics that spontaneously form bone mineral) may spontaneously 
produce minerals that cluster locally as small lumps. 
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The most intense medial artery calcifications (1b) are observed in patients with diabetes 
and chronic renal disease (Reaven 2005; Okuno 2007). An important role in the medial 
calcification process is attributed to metalloproteinases (MMP), which are secreted by 
adventitial/medial inflammatory cells. MMP activity causes an increase in elastin 
matabolites, which promote further inflammation and may become crystallization 
nucleators (Lee 2006). MMP inhibition breaks the vicious cycle of monocyte activation 
and restricts vascular calcification. At any chance, elastin degradation appears early in 
many forms of elastic calcification. 
During aging, medial calcification may develop by unknown etiology, or result from 
associated conditions such as chronic renal failure, atherosclerosis, insulin resistance, 
etc. (Demer 2008). 
 
The plaques with a predominant core calcification are classified as AHA type Vb 
according to the 1995 Stary's classification or AHA type VII according to the 2000 
Stary's classification. The idea that led to this modification is that events such as 
calcification or fibrosis could represent regressive processes, "extinguishing" the type 
IV, V, or VI plaques. At any chance, the clinical impact of a plaque in which both 
calcification and histological complications coexist is far from being clarified. 
According to our data calcified plaques showed less flogosis, a smaller lipid core, and 
less neoangiogenesis than other plaques, but with the same incidence of hemorrhage, 
thrombosis and surface defects. Yet, interestingly, in these plaques complications are 
not correlated with clinical plaque instability that we evaluated as symptomatology and 
focal brain lesions, since their incidence is sensibly lower regardless the intra-plaque 
complications. 
This is noteworthy, since the presence of calcifications seems to imply a sort of 
“protection” towards complications in these plaques, so that they show a much lower 
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incidence of TIA and stroke at clinical onset, as well as focal brain lesions at CT. For 
these reasons, in our opinion, these plaques can be classified among the type VII 
plaques, instead of type VI, at least on clinical grounds. Alternatively, they can be 
classified as type VI, but the extension of the calcifications should be stated in the 
pathological report, to highlight their protective nature. 
The finding that extensive calcifications protect the plaque can lay in the big dimensions 
of the calcifications, in accordance with recent papers that showed that small coronary 
calcifications increase the probability of plaque rupture, while individual, large 
calcifications make the plaque more stable (Huang 2001; Vengrenyuk 2006). The 
reason why the neoangiogenesis and the pathological complications do not affect 
symptomatology remains unclear, but it is possible that the hemorrhages and erosions 
found in these plaques might have a different pathogenesis. For example, it is possible 
that they can be due directly by the mechanical stresses of the calcified mass, and not by 
immature neoangiogenesis and endothelial damage. Another possible explanation is that 
the "calcified type VI" plaques can represent an early stage of type VII plaques, in 
which the regressive process is more recent, and the complications are not disappeared 
yet. 
 
The last result that emerged from our data is that 50% of the female patients had 
calcified plaques, showing a significantly lower incidence of symptoms, CT positivity 
and type VI plaques than the male patients. Ten years ago, Allison et al. have found 
53% and 30% prevalence of "zero calcification" in female and male patients 
respectively before age 50: after that age the prevalence of a diffuse vessel calcification 
increases, in a linear fashion in males and exponentially in females (Allison 2004). 
Actually, female sex hormones play an important role in bone tissue metabolism, 
increasing bone density and inhibiting osteoclast activity. Estrogen therapy for post-
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menopausal women reduces vascular calcifications, probably due to the effects on the 
risk factors, but also to a direct genomic and extragenomic effect on macrophages, 
endothelial cells and smooth muscle cells (Mackey 2005; Manson 2007; Jeon 2010). 
Nevertheless, it should be kept in mind that most women in our series were post-
menopausal, and their age at the moment of surgery did not differ from males (70.2±9.5 
versus 71.0±8.5 years), so the question whether the post-menopausal hormone therapy 
might play a role in the pathophysiology of the atherosclerosis is still open. 
 
In conclusion, this thesis confirms that the neovessels of atheromatous plaques express a 
double Nestin/WT1 phenotype, and that the Nestin+/WT1- phenotype characterizes the 
plaques with features of instability, regardless the real amount of the neoangiogenesis 
(expressed as CD34-positive vessels). The plaques with massive calcifications show the 
same incidence of histological complications, but they do not influence 
symptomatology and plaque vulnerability. Female patients show a much higher 
incidence of not-complicated or calcified plaques, receiving de facto a sort of protection 
compared to male patients. 
 
A possible translational application of these findings could be a comparison between the 
plaque dynamic imaging and the histological assessment of calcification, to evaluate the 
possibility of a pre-surgical risk stratification of patients, basing on their sex, risk 
factors and intra-plaque calcification. The pre-surgical identification of those patients at 
major risk of developing stroke or brain lesions is likely to make more rational the 
priority for endarterectomy. 
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